Vascular Solutions Surpasses 50,000 Successfully

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vascular Solutions Surpasses 50,000 Successfully Reprocessed ClosureFAST(R) Catheters

-- Reprocessing of popular vein treatment catheter results in significant cost savings and reduced medical waste for U.S. vein clinics
-- Excellent safety record established, with no serious adverse patient events reported since reprocessing began in January of 2012 
-- Vascular Solutions offers a complete package of accessory products for ClosureFAST vein ablation procedures

MINNEAPOLIS, April 9, 2014 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq: VASC ) today announced that more than 50,000 ClosureFAST catheters have been successfully reprocessed by its partner, Northeast Scientific, Inc. (NES), since Vascular Solutions launched the reprocessing service for the popular vein ablation catheters in January 2012.

"The benefits and reliability of our reprocessing service for the ClosureFAST catheter are extremely clear, and as a result a growing number of U.S. vein clinics are adopting this service as a way to significantly reduce their costs and cut down on medical waste," said Howard Root, Chief Executive Officer of Vascular Solutions. "During more than two years since this novel service was launched, we have demonstrated an excellent safety record, with more than 50,000 catheters successfully reprocessed and no serious adverse patient events reported."

Reprocessing of the ClosureFAST catheter is a service offered exclusively by Vascular Solutions in collaboration with NES. To date, more than 500 U.S. vein practices have contracted with Vascular Solutions to have their ClosureFAST catheters reprocessed by NES.

"Our reprocessing partner, NES, has done an excellent job of meeting physicians' demands for a reliable source of reprocessed ClosureFAST catheters," Mr. Root said. "We are very pleased with the results of our ClosureFAST reprocessing program and we look forward to continued success with this service."

The ClosureFAST radiofrequency ablation catheter, which is manufactured and marketed by Covidien, is the most popular product used for performing endovenous therapy for the treatment of varicose veins in the U.S. Vascular Solutions is offering the reprocessing service under contract with NES, an established third-party reprocessor of medical devices. NES received 510(k) clearance from the U.S. Food and Drug Administration on November 30, 2011 for reprocessing the ClosureFAST catheter.

Craig Allmendinger, Chief Executive Officer of NES, commented: "Reprocessing is one of the fastest-growing segments of the medical device industry, and the vast majority of U.S. hospitals are now contracting with third-party reprocessors for a number of single-use medical devices because of the proven results. Since the ClosureFAST reprocessing service was launched more than 26 months ago, it has achieved a high level of acceptance among physicians as we have demonstrated the ability to meet the highest performance standards."

Vascular Solutions markets and sells the ClosureFAST reprocessing service to hospitals and clinics in the United States through Vascular Solutions' 91-person direct sales force. Subscribers to the service send their used ClosureFAST catheters directly to NES for reprocessing. NES's validated reprocessing system for ClosureFAST involves multiple stages, including decontamination, cleaning, drying, packaging, labeling, sterilization, and biological quarantine testing. As part of the process, each catheter is subjected to function testing and undergoes multiple inspections to ensure that quality standards are met.

In addition to supporting its Vari-Lase® laser ablation product line and offering the ClosureFAST reprocessing service, Vascular Solutions offers a full range of accessory products that are needed to perform both RF- and laser-based procedures. The company provides procedure packs that are designed specifically for either RF or laser procedures, micro-introducers and 7F Micro-HV kits, 0.018" and 0.025" guidewires and the Auto-Fill® Syringe and Klein Pump kits for administering tumescent anesthesia. Vascular Solutions also sells a line of disposable vein hooks for use in phlebectomy procedures and the Veinsite® system used to visualize veins beneath the skin surface.

About Northeast Scientific

Northeast Scientific, Inc. (NES), a privately-held company headquartered in Waterbury, Connecticut, is registered with the U.S. Food and Drug Administration as a reprocessor of single-use medical devices. Founded in 2005, NES received its first 510(k) clearance in 2007. NES's facility was designed specifically to reprocess single-use devices. The process employs a high capacity reverse osmosis deionized water system for cleaning, and only environmentally safe detergents are used. NES performs all sterilization in-house using 100% ethylene oxide systems that limit waste and ensure sterility. Functional testing of each reprocessed device and heat-seal packaging is carried out in NES's Class 10,000 clean room. For more information about NES, visit the company's website at www.mdreprocess.com .

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 80 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2013 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.

ClosureFAST is a registered trademark of Covidien LP Limited Partnership. Reprocessing of ClosureFAST catheters is performed by Northeast Scientific and is not affiliated in any way with Covidien.

For further information, connect to www.vasc.com .

Phil Nalbone, VP-Corp. Dev. (763) 656-4371

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 469

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 181

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 848

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 117

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 423

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 734

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 176

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 51

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
WAVE Life Sciences: Rising Share Value Amid DMD Innovations

Updated Category News Views 50

Recent Developments at WAVE Life Sciences B.Riley has maintained a Buy rating on WAVE Life Sciences (NASDAQ: WVE) and raised the price target to $19 from $11. This adjustment comes after the promising announcement regarding the company's Duchenne muscular dystrophy (DMD) drug candidate, WVE-N531. Promising DMD Drug Candidate The company's analyst highlighted an increase...

Continue Reading
First American Uranium Successfully Secures $2.86 Million Funding

Updated Category News Views 143

First American Uranium Secures Oversubscribed Financing First American Uranium Inc. is thrilled to announce the closing of its oversubscribed flow-through share financing, having raised an impressive $2.86 million from issuing a total of 2,073,262 flow-through shares. Each share was priced at $1.38, exceeding initial expectations. Funding Utilization for Exploration The...

Continue Reading
Community Healthcare Trust Reports Q2 Financial Results

Updated Category News Views 161

Summary of Financial Results Community Healthcare Trust Incorporated (NYSE: CHCT) recently announced its financial performance for the quarter ending June 30, 2025. The company reported a net loss of approximately $12.6 million or $0.50 per diluted common share. The funds from operations ("FFO") and adjusted funds from operations ("AFFO") during this period amounted to...

Continue Reading
Neuberger Fund Ups Distribution Amid Market Challenges

Updated Category News Views 169

Neuberger Boosts Distribution: What's Driving This? I ain't about to sugarcoat it: the Neuberger Next Generation Connectivity Fund (NYSE: NBXG) decided to jack up its monthly distribution rate to $0.132 per share. This announcement, hitting wallets on November 30, 2026, has a record and ex-date of November 16. Now, that's a good ol' reliable payout for folks holding NBXG...

Continue Reading